



SCIENTIFIC MEETING ABEC/BVSK –  
31/01/2010

**LIST OF POSTERS PRESENTATIONS**

- 1. REACHING HIGHER PARTICIPATION RATES IN CERVICAL CANCER SCREENING BY VAGINAL SELF-SAMPLING FOR HPV DETECTION: COMPARISON OF TWO SAMPLING DEVICES.**  
**Marc F.D. Baay**<sup>1</sup>, Filip Lardon<sup>1</sup>, Paul Van Royen<sup>2</sup>, Willem J.G. Melchers<sup>3</sup>, Jan B. Vermorken<sup>1,4</sup>, and Veronique Verhoeven<sup>2</sup>  
<sup>1</sup> *Laboratory for Cancer Research and Clinical Oncology, University Antwerp, Wilrijk, Belgium,* <sup>2</sup> *Centre for General Practice, University Antwerp, Wilrijk, Belgium,* <sup>3</sup> *Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands,* <sup>4</sup> *Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium*  
*Corresponding author: Marc Baay, University Antwerp, Laboratory for Cancer Research and Clinical Oncology, Universiteitsplein 1 (T3.11), B2610 Wilrijk  
Belgium, phone +32 3820 2576, e-mail marc.baay@ua.ac.be*
- 2. MULTIPLE EFFECTS OF OSTEOBLAST-LIKE CELLS ON BREAST CANCER CELLS TO ENHANCE BONE METASTASIS PROGRESSION**  
**Hichame Id Boufker**<sup>1</sup>, Mehdi Najar<sup>1</sup>, Laurence Lagneaux<sup>1</sup>, Hugues Duvillier<sup>1</sup>, Rouas Redouane<sup>1</sup>, Fayyad-Kazan Hussein<sup>1</sup>, Murielle Wiedig<sup>1</sup>, Ghanem Ghanem<sup>1</sup>, Jean-Jacques Body<sup>2</sup>, **Fabrice Journée**<sup>1</sup>  
<sup>1</sup>*Institut Jules Bordet, Bruxelles, Belgique,* <sup>2</sup>*CHU-Brugmann, Bruxelles, Belgique*
- 3. IDENTIFICATION OF MARKERS IN MELANOMA LINES TO PREDICT RESPONSE TO THE TYROSINE KINASE INHIBITOR DASATINIB**  
**Fabrice Journée**<sup>1</sup>, Murielle Wiedig<sup>1</sup>, Rénato Morandini<sup>1</sup>, François Salès<sup>1</sup>, Alain Spatz<sup>2</sup>, Martine Piccart<sup>3</sup>, Ahmad Awada<sup>3</sup>, Ghanem Ghanem<sup>1</sup>  
<sup>1</sup>*Laboratoire d'Oncologie et de Chirurgie Expérimentale,* <sup>3</sup>*Clinique d'Oncologie Médicale, Institut Jules Bordet, ULB, Brussels, Belgium;* <sup>2</sup>*Departments of Pathology & Oncology, McGill University, Montréal, Canada*
- 4. EXPLOITING THE BH4 DOMAIN OF BCL-2 AS A NOVEL STRATEGY TO PROVOKE PRO-APOPTOTIC CA<sup>2+</sup> SIGNALING IN CANCER CELLS**  
Giovanni Monaco, Haidar Akl, Tim Ulens, Yi-Ping Rong, Jan B. Parys, Ludwig Missiaen, Humbert De Smedt, Marc De Maeyer, Clark W. Distelhorst & **Geert Bultynck**  
[geert.bultynck@med.kuleuven.be](mailto:geert.bultynck@med.kuleuven.be) – *Laboratory of Molecular and Cellular Signaling, Campus Gasthuisberg O/N1, K.U.Leuven, B-3000 Leuven, Belgium.*

- 5. RNA INTERFERENCE TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR AND EVALUATION OF BIOLOGICAL EFFECTS IN LUNG CANCER CELLS**  
**Gang Chen\***, Peter Kronenberger\*<sup>§</sup>, Erik Teugels\* and Jacques De Grève\*  
 \*Laboratory of Molecular Oncology and Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium  
<sup>§</sup>Laboratory for Biotechnology, Department of Gezondheidszorg, Erasmushogeschool Brussel, Brussels, Belgium.
- 6. TARGAN : BIOCOMPATIBILITY ASSESSMENT OF 3 TYPES OF GOLD NANOPARTICLES ON ENDOTHELIAL CELLS**  
**M. Crespin<sup>(1)</sup>**, O. Feron<sup>(2)</sup>, B. Gallez<sup>(3)</sup>, B. Masereel<sup>(4)</sup>, T. Vander Borgh<sup>(5)</sup>, S. Lucas<sup>(6)</sup> and C. Michiels<sup>(1)</sup>  
 CRESPIN Marianne : presenting author – e-mail : [marianne.crespin@fundp.ac.be](mailto:marianne.crespin@fundp.ac.be)  
*Unité de Recherche en Biologie Cellulaire (URBC), FUNDP University of Namur, Belgium*  
*Unité de Pharmacothérapie (FATH), Université catholique de Louvain, Belgium*  
*Laboratoire de résonance magnétique biomédicale (CMFA), Université catholique de Louvain, Belgium*  
*Département de Pharmacie (DP), FUNDP University of Namur, Belgium*  
*Center of Molecular Imaging and Experimental Radiotherapy (IRME), Université catholique de Louvain, Belgium*  
*Research center in Physics of Matter and Radiation (PMR), Laboratoire d'Analyses par Réactions Nucléaires (LARN), FUNDP University of Namur, Belgium*
- 7. LAT-1 EXPRESSION AND 4-FMP PET IMAGING IN COLORECTAL CANCER**  
**M. De Ridder**, K. Law, H. Everaert, A. Sermeus, V. Verovski, A. Hoorens, M. Vermeersch, H. Jiang, K. Kersemans, J. Mertens, D. Verellen & G. Storme.  
 UZ-Brussel, Vrije Universiteit Brussel ([mark.deridder@uzbrussel.be](mailto:mark.deridder@uzbrussel.be))
- 8. ACTIVATED MACROPHAGES AS A NOVEL DETERMINANT OF TUMOR CELL RADIORESPONSE: THE ROLE OF NITRIC OXIDE-MEDIATED INHIBITION OF CELLULAR RESPIRATION AND OXYGEN SPARING**  
**H. Jiang<sup>1</sup>**, M. De Ridder<sup>1</sup>, V.N. Verovski<sup>1</sup>, P. Sonveaux<sup>2</sup>, B.F. Jordan<sup>2</sup>, M. Vermeersch<sup>1</sup>, K. Law<sup>1</sup>, C. Monsaert<sup>1</sup>, D.L. Van den Berge<sup>1</sup>, D. Verellen<sup>1</sup>, O. Feron<sup>2</sup>, B. Gallez<sup>2</sup> and G.A. Storme<sup>1</sup>  
<sup>1</sup>UZ-Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Brussels;  
<sup>2</sup>Unit of Pharmacology and Therapeutics, Université catholique de Louvain, Avenue E. B-1200 Brussels
- 9. DUSPs AS MARKERS OF MEK/ERK ACTIVATION IN PRIMARY COLORECTAL CANCER AND POTENTIAL ROLE AS OUTCOME PREDICTORS AFTER EGFR PATHWAY TARGETED THERAPY IN METASTATIC COLORECTAL CANCER**  
**Wendy De Roock<sup>1</sup>**, Bart Jacobs<sup>1</sup>, Mark Janssens<sup>2</sup>, Bart Biesman<sup>1</sup>, Jef De Schutter<sup>1</sup>, Eric Van Cutsem<sup>3</sup>, Sabine Tejpar<sup>3</sup>  
<sup>1</sup>Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, BELGIUM  
<sup>2</sup>Independent biostatistician, Mechelen, BELGIUM  
<sup>3</sup>Digestive Oncology Unit, Gasthuisberg University Hospital, Katholieke Universiteit Leuven, Leuven, BELGIUM

**10. HIGH QUALITY ASSESSMENT OF *KRAS* MUTATIONS AND THEIR PROGNOSTIC VALUE IN ARCHIVAL COLORECTAL CANCER TISSUES USING HIGH RESOLUTION MELTING ANALYSIS.**

**Vanessa Deschoolmeester**<sup>1</sup>, Carolien Boeckx<sup>1</sup>, Wim Wuyts<sup>2</sup>, Eric Van Marck<sup>3</sup>, Peter Vermeulen<sup>4</sup>, Filip Lardon<sup>1</sup>, Jan B. Vermorken<sup>1</sup> and Marc Baay<sup>1</sup>.

<sup>1</sup>Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp (UA/UZA), Wilrijk, Belgium,

<sup>2</sup>Department of Medical Genetics, University of Antwerp (UA/UZA), Wilrijk, Belgium, <sup>3</sup>Department of Pathology, University Hospital of Antwerp (UZA),

Edegem, Belgium, <sup>4</sup>Translational Cancer Research Group, Oncology Center, General Hospital St Augustinus, Wilrijk, Belgium

[Vanessa.deschoolmeester@ua.ac.be](mailto:Vanessa.deschoolmeester@ua.ac.be)

**11. GENE PROFILING IN CIDOFOVIR-TREATED AND CIDOFOVIR-RESISTANT SiHA CERVICAL CARCINOMA CELLS**

**T. De Schutter**, D. Topalis, G. Andrei & R. Snoeck

Laboratory of Virology, Rega Institute for Medical Research, K.U.Leuven, Belgium

**12. OSTEOPONTIN EXPRESSION IS REGULATED IN HUMAN GLIOMA CANCER STEM CELLS**

**Dewald Manuela**<sup>1</sup>, Lamour Virginie<sup>1</sup>, Kroonen Jérôme<sup>2</sup>, Rogister Bernard<sup>2</sup>, Castronovo Vincent<sup>1</sup> and Bellahcène Akeila<sup>1</sup>

<sup>1</sup> GIGA-Cancer, Metastasis Research Laboratory and <sup>2</sup> GIGA-Neurosciences, University of Liège, Belgium

**13. ANTI-APOPTOTIC ROLE OF HIF-1 AND AP-1 IN PACLITAXEL EXPOSED BREAST CANCER CELLS UNDER HYPOXIA**

**Lionel FLAMANT**, Annick NOTTE, Noelle NINANE, Martine RAES, Carine MICHIELS\*

Email addresses: Lionel Flamant, [lionel.flamant@fundp.ac.be](mailto:lionel.flamant@fundp.ac.be); Annick Notte, [annick.notte@fundp.ac.be](mailto:annick.notte@fundp.ac.be); Noelle Ninane, [noelle.ninane@fundp.ac.be](mailto:noelle.ninane@fundp.ac.be); Martine Raes, [martine.raes@fundp.ac.be](mailto:martine.raes@fundp.ac.be); Carine Michiels, [carine.michiels@fundp.ac.be](mailto:carine.michiels@fundp.ac.be)

Corresponding author

Laboratory of Biochemistry and cellular Biology (URBC), University of Namur-FUNDP, 61 rue de Bruxelles, 5000 Namur, Belgium

Tel 32-81-724131

Fax 32-81-724135

**14. PREVALENCE AND CLINICAL SIGNIFICANCE OF SOMATIC MUTATION HOT SPOTS IN ENDOMETRIAL CARCINOMA**

**Diego Garcia**<sup>1,2</sup>, Ingrid Vandepuut<sup>2</sup>, An Capoen<sup>3</sup>, Bart Claes<sup>1</sup>, Eric DeJonghe<sup>4</sup>, Betul Yesilgurt<sup>1</sup>, Jessica Billen<sup>2</sup>, Gilian Peuteman<sup>1</sup>, Raf Sciot<sup>3</sup>, Peter Van Eycken<sup>4</sup>, Ignace Vergote<sup>2</sup>, Diether Lambrechts<sup>1</sup>, Frederic Amant<sup>2</sup>.

<sup>1</sup> Vesalius Research Center, VIB and K.U.Leuven, Leuven, Belgium

<sup>2</sup> Gynaecologic Oncology, University Hospital Leuven, Leuven, Belgium

<sup>3</sup> Department of Pathology, University Hospital Leuven, Leuven, Belgium

<sup>4</sup> Department of Pathology, East Limburg Hospital, Genk, Belgium

*Abstract correspondence: [diegoandres.garciadios@med.kuleuven.be](mailto:diegoandres.garciadios@med.kuleuven.be)*

**15. HYPERICIN-PDT TREATMENT OF CANCER CELLS LEADS TO SURFACE EXPOSURE/EXTRACELLULAR RELEASE OF DAMPS AND ACTIVATES HUMAN IMMATURE DENDRITIC CELLS**

**Abhishek D. Garg**<sup>1,\*</sup>, Tom Verfaillie<sup>1</sup>, Noemi Rubio<sup>1</sup>, Gabriela B. Ferreira<sup>2</sup>, Chantal Mathieu<sup>2</sup> and Patrizia Agostinis<sup>1,\*\*</sup>

<sup>1</sup> Cell Death Research and Therapy (CDRT) Lab, Dept. Molecular Cell Biology, K. U. Leuven, Leuven, Belgium; <sup>2</sup> Laboratory for Experimental Medicine and Endocrinology (LEGENDO), K.U. Leuven, Leuven, Belgium; (\*\* [patricia.agostinis@med.kuleuven.be](mailto:patricia.agostinis@med.kuleuven.be))

(\* Presenting author - CDRT Lab, Dept. Molecular Cell Biology, Campus Gasthuisberg O&N1, Herestraat 49, Box 901, Leuven, Belgium; email – [abhishek.garg@med.kuleuven.be](mailto:abhishek.garg@med.kuleuven.be))

**16. SPECIFIC HDAC5 INHIBITION SENSITIZES CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS**

**Sylvie HASTIR**, Sophie PIROTTE, Vincent CASTRONOVO and Denis MOTTET, Ulg.

**17. SCREENING FOR ANDROGEN RECEPTOR ANTAGONISTS TO IMPROVE PROSTATE CANCER THERAPY**

Helsen C<sup>1</sup>, Haelens A<sup>1</sup>, Denayer S<sup>1</sup>, Van Tilborgh N<sup>1</sup>, Kerkhofs S<sup>1</sup>, Clinckemalie L<sup>1</sup>, Spans L<sup>1</sup>, Munck S<sup>2</sup>, Chaltin P<sup>3</sup>, Marchand A<sup>3</sup> and **Claessens F<sup>1</sup>**

1 - Molecular Endocrinology Laboratory, Department of Molecular Cell Biology, KULeuven, Belgium

2 - Department of developmental and molecular genetics, KULeuven, Belgium

3 - Centre of Drug Design and Development (CD3), KULeuven, Belgium

**18. DETECTION AND CHARACTERIZATION OF PROSTATIC CARCINOMA BY MEANS OF DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (DCE-MRI).**

**Isebaert S.**<sup>1</sup>, De Keyzer F.<sup>2</sup>, Haustermans K.<sup>1</sup>, Lerut E.<sup>3</sup>, Roskams T.<sup>3</sup>, Roebben I.<sup>2</sup>, Van Poppel H.<sup>4</sup>, Joniau S.<sup>4</sup>, Oyen R.<sup>2</sup>

<sup>1</sup>Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium

<sup>2</sup>Department of Radiology, University Hospitals Leuven, Leuven, Belgium

<sup>3</sup>Department of Histopathology, University Hospitals Leuven, Leuven, Belgium

<sup>4</sup>Department of Urology, University Hospitals Leuven, Leuven, Belgium

*Presenting author* : Sofie Isebaert - Lab of Experimental Radiotherapy - University Hospitals Leuven Campus Gasthuisberg - CDG building, 8<sup>th</sup> floor, box 815 - Herestraat 49 - 3000 Leuven - Sofie.Isebaert@med.kuleuven.be

**19. THE TUMOR SUPPRESSOR PP2A AB IS INVOLVED IN DOUBLE-STRAND BREAK DNA REPAIR**

**Pieter Kaley**, Anna Sablina, kuleuven.

**20. EXPERIMENTAL DETERMINATION OF THE RELATIVE RADIAL DOSE DISTRIBUTION IN HIGH GRADIENT REGIONS AROUND IRIIDIUM-192 WIRE SOURCE. COMPARISON BETWEEN ELECTRON PARAMAGNETIC RESONANCE IMAGING, GAFCHROMIC EBT FILM DOSIMETRY AND MONTE-CARLO SIMULATIONS.**

**N. Kolbun**<sup>1</sup>, P. Levêque<sup>1</sup>, F. Abboud<sup>2</sup>, S. Vynckier<sup>2</sup>, and B. Gallez<sup>1</sup>

<sup>1</sup>Biomedical Magnetic Resonance Unit, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium, <sup>2</sup>Molecular Imaging and Experimental Radiotherapy Unit, Université catholique de Louvain, Brussels, Belgium

**21. GENE EXPRESSION PROFILING OF EX VIVO IFN-ALPHA RESPONSE IN PRIMARY CELLS FROM ADULT T-CELL LEUKEMIA PATIENTS**

**Ricardo Khouri**<sup>1,2</sup>, Daniele Decanine<sup>2</sup>, Lourdes Farre<sup>2</sup>, Achiléa Bittencourt<sup>3</sup>, Anne-Mieke Vandamme<sup>1</sup>, Johan Van Weyenbergh<sup>1,2</sup>

<sup>1</sup>Rega Institute for Medical Research, K.U. Leuven, Belgium; <sup>2</sup>CPqGM-FIOCRUZ, <sup>3</sup>HUPES-UFBA, Salvador-BA, Brazil.

**22. MyD88, TLR-2, TLR-9 AND TNFR1-DEPENDENT SIGNALING IS ESSENTIAL FOR THE STERILE INFLAMMATORY RESPONSE TRIGGERED BY DOXORUBICIN**

Dmitri V. Krysko,<sup>1,2#</sup> **Agnieszka Kaczmarek**,<sup>1,2\*#</sup> Jerzy Woznicki,<sup>1,2</sup> Stefan Magez,<sup>3,4</sup> Olga Krysko,<sup>5</sup> Pieter Bogaert,<sup>1,2</sup> Peter Vandenamee<sup>1,2</sup>

\*Presenting author; #these authors contributed equally to the work

<sup>1</sup>Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, 9052 Ghent, Belgium; <sup>2</sup>Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium;

<sup>3</sup>Laboratory for Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; <sup>4</sup>Department of Molecular and Cellular

Interactions, VIB, Brussels, Belgium; <sup>5</sup>Upper Airway Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium

E-mail: Agnieszka.Kaczmarek@dmb.vib-UGent.be

**23. DENTIN SIALOPHOSPHOPROTEIN IS EXPRESSED IN HUMAN GLIOBLASTOMA**

**V. Lamour**<sup>1</sup>, M. Deprez<sup>2</sup>, E. Bianchi<sup>2</sup>, V. Castronovo<sup>1</sup> and A. Bellahcène<sup>1</sup>

<sup>1</sup>GIGA-Cancer, Metastasis Research Laboratory, University of Liège and

<sup>2</sup>Laboratory of Neuropathology, Department of Pathology, CHU, Liège, Belgium

**24. CROSS TALK BETWEEN DENDRITIC AND NATURAL KILLER CELLS IN THE PRESENCE OF VACCINE AGENT AGAINST CERVICAL CANCER.**

**I. Langers**, V. Renoux, A. Reschner, E. Dortu, J. Boniver, P. Delvenne, N. Jacobs.

Dept. of Experimental Pathology, Giga-Cancer/I3, University of Liège.

**25. HEREDITARY BREAST AND/OR OVARIAN CANCER: EXTENSION OF THE MOLECULAR TESTING TO THE CHEK2 GENE AND ITS IMPLICATION IN THE CLINICAL SERVICE**

**Geneviève Michils**<sup>1</sup>, Magdalena Chmara<sup>1</sup>, Karin Leunen<sup>2</sup>, Gert Matthijs<sup>1</sup> and Eric Legius<sup>1</sup>

Center for Human Genetics, University Hospital Leuven, Leuven, Belgium

Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium

Presenting author: Geneviève Michils, Center for Human Genetics, UZ Leuven, Campus Gasthuisberg, Herestraat, 49 – B-3000 Leuven. Email: genevieve.michils@uzleuven.be

**26. AN *IN VITRO* MODEL CLOSELY MIMICKING PATIENT RESPONSE TO COMBINATION THERAPY OF AZT AND IFN- $\alpha$  FOR ADULT T-CELL LEUKAEMIA/LYMPHOMA**

**Britta Moens**<sup>1</sup>, Kimberly Dée<sup>1</sup>, Kris Covens<sup>1</sup>, Ricardo Khouri<sup>1</sup>, Christophe Pannecouque<sup>2</sup>, Anne-Mieke Vandamme<sup>1</sup>, Johan Van Weyenbergh<sup>1</sup>

Affiliation: <sup>1</sup>Laboratory for Clinical and Epidemiological Virology and <sup>2</sup>Laboratory for Virology and Chemotherapy, Rega Institute for Medical Research K.U. Leuven.

Presenting author: Britta Moens - Laboratory of Clinical and Epidemiological Virology  
Department of Microbiology and Immunology - Rega Institute for Medical Research –  
KULeuven

Minderbroedersstraat 10 - BE-3000 Leuven, Belgium

**27. DETECTION OF IDH1 GENE MUTATIONS IN HIGH-GRADE GLIOMA IN A PHASE II CETUXIMAB TRIAL**

**Shasha Ly**, Jan Sadones, Erik Teugels, Bart Neyns, Jacques De Grève  
Laboratory of Molecular Oncology and Department of Medical Oncology,  
Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels,  
Belgium.

**28. KERATIN 19 EXPRESSION IN HEPATOCELLULAR CARCINOMA IS CORRELATED WITH POSTOPERATIVE TUMOUR RECURRENCE AND METASTASIS MARKERS.**

**Bart Spee**<sup>1</sup>, Olivier Govaere<sup>1</sup>, Ann Durnez<sup>1</sup>, Carl Janssen<sup>1</sup>, Sara Vanderborgh<sup>1</sup>, Chris Verslype<sup>2</sup>, Raymond Aerts<sup>3</sup>, Baki Topal<sup>4</sup>, Frederic Nevens<sup>2</sup>, Valeer J. Desmet<sup>1</sup>, Snorri S. Thorgeirsson<sup>3</sup>, Tania Roskams<sup>1</sup>.

<sup>1</sup>Department of Morphology and Molecular Pathology, <sup>2</sup>Department of Hepatology,

<sup>3</sup>Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium

<sup>4</sup>Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer

Institute, National Institutes of Health, Bethesda, MD, USA.

Corresponding author: Dr. B.Spee

Department of Morphology and Molecular Pathology, University Hospitals Leuven

Minderbroederstraat 12

B3000, Leuven (Belgium)

Tel.: +32 16 336644 ; Fax: +31 30 2518126 ; Email: B.Spee@uu.nl

**29. STUDY OF THE TUMOR VASCULAR-DISRUPTING EFFECTS OF TNF AND IFN-GAMMA.**

**Leander Huyghe**<sup>1#</sup>, Bram De Craene<sup>2</sup>, Geert Berx<sup>2</sup>, and Peter Brouckaert<sup>1</sup>

<sup>1</sup>Molecular Pathophysiology and Experimental Therapy Unit, <sup>2</sup>Molecular and Cellular Oncology Unit, VIB Department of Molecular Biomedical Research, Ghent University, Technologiepark 927, 9052 Zwijnaarde, Belgium.

<sup>#</sup>leander.huyghe@dmb.vib-ugent.be

**30. IDENTIFICATION OF CYTOTOXIC EFFECTS OF HYDROLYZED PECTIN IN HEPG2 AND A549 CELLS**

**L. Leclere**<sup>1</sup>, J. C. Cabrera Pino<sup>2</sup>, P. Van Cutsem<sup>2</sup>, C. Michiels<sup>1</sup>

1- Laboratory of Biochemistry and Cellular Biology, University of Namur, 61 rue de Bruxelles, B-5000 Namur, Belgium. E-mail : lleclere@fundp.ac.be

2- Laboratory of Plant Cellular and Molecular Biology, University of Namur, 61 rue de Bruxelles, B-5000 Namur, Belgium.

Presenting author : *Leclere Lionel* - e-mail: Leclere.lionel@fundp.ac.be

**31. TARGETING RADIOTHERAPY TO CANCER VIA SMALL NECROSIS AVID MOLECULES: A GENERALIZED APPROACH TO IMPROVED TREATABILITY AND CURABILITY ?**

**\*Yicheng Ni**, Junjie Li, Huaijun Wang, Feng Chen, Marlein Miranda Cona, Thierry Marysael, Peter de Witte, Kristof Prinsen, Guy Bormans, Alfons Verbruggen, Lin Zhou, Johan Nuyts, Guy Marchal, <sup>a</sup>Ziping Sun, <sup>b</sup>Jian Zhang, <sup>c</sup>Haibo Shao, and <sup>c</sup>Ke Xu

University of Leuven, Belgium; <sup>a</sup>Shandong Academy of Medical Sciences, <sup>b</sup>Jiangsu Academy of Traditional Chinese Medicine, and <sup>c</sup>China Medical University, China

**32. SURVIVAL FRACTION AND GENE EXPRESSION PATTERN IN HUMAN LUNG CARCINOMA A549 CELLS AFTER X-RAYS AND ALPHA PARTICLE IRRADIATIONS**

**H. Riquier**<sup>1</sup>, A-C. Wéra<sup>2</sup>, O. Feron<sup>3</sup>, S. Lucas<sup>2</sup>, C. Michiels<sup>1</sup>

*Laboratoire de Biochimie et Biologie cellulaire*<sup>1</sup>, *Laboratoire d'Analyses par Réactions Nucléaires*<sup>2</sup>, *Université de Namur - FUNDP, 61 rue de Bruxelles, 5000 Belgium.*

*Laboratoire de Pharmacothérapie*<sup>3</sup> – *UCL, 52 Avenue Emmanuel Mounier, 1200 Woluwé-Saint-Lambert. E-mail : helene.riquier@fundp.ac.be*

**33. DE NOVO LIPOGENESIS IN CANCER CELLS IMPAIRS THE FORMATION OF THE PRIMARY CILIUM AND DISTORTS CELL AND TISSUE DEVELOPMENT**

**Evelien Rysman**<sup>1\*</sup>, Nicolas Willemarck<sup>1,2\*</sup>, Kris Vleminckx<sup>2</sup>, and Johannes V. Swinnen<sup>1</sup>

<sup>1</sup>Laboratory for Experimental Medicine and Endocrinology, Department of Experimental Medicine, Campus Gasthuisberg, Katholieke Universiteit Leuven, 3000 Leuven, Belgium

<sup>2</sup>Department of Molecular Biomedical Research, VIB, 9000 Ghent, Belgium and Department of Biomedical, Molecular Biology, Ghent University, 9000 Ghent, Belgium

**34. GLUCOSE-INDEPENDENT ACTIVITY OF CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN CONTRIBUTES TO ENHANCED LIPOGENESIS AND CELL SURVIVAL IN PROSTATE CANCER CELLS**

**Katryn Scheys**<sup>1</sup>, Frank Vanderhoydonc<sup>1</sup>, Ludo Deboel<sup>1</sup>, Steven Joniau<sup>2</sup>, Raymond Oyen<sup>3</sup>, Hein Van Poppel<sup>2</sup>, Guido Verhoeven<sup>1</sup>, Johannes V. Swinnen<sup>1</sup>

<sup>1</sup>*Laboratory for Experimental Medicine and Endocrinology, K.U.Leuven, Leuven, Belgium*

<sup>2</sup>*Urology Section, UZ Leuven, Leuven, Belgium*

<sup>3</sup>*Radiology Section, UZ Leuven, Leuven, Belgium*

*Katrijn.Scheys@med.kuleuven.be*

- 35. CIRCULATING TUMOR CELLS FROM PANCREATIC CANCER HAVE AN ACTIVATED P38 MAPK SIGNALING AND UPREGULATED CELL MOTILITY**  
**Sergeant G** [1] ; van Eijdsden R [2] ; Roskams T [3] ; Van Duppen V [4] ; Van Pelt J [5] ; Topal B [1]

Affiliations:

[1] Department of Abdominal Surgery, University Hospital Leuven, Leuven, Belgium

[2] VIB Microarray Facility, K.U.Leuven, Leuven, Belgium

[3] Department of Pathology, University Hospital Leuven, Leuven, Belgium

[4] Laboratory of Experimental Hematology, K.U.Leuven, Leuven, Belgium

[5] Laboratory of Hepatology, K.U.Leuven, Leuven, Belgium

- 36. REGULATION OF P53 EXPRESSION IN HYPOXIC CANCER CELLS INCUBATED WITH ETOPOSIDE**

**A.Sermeus**, J.-P. Cosse, M. Raes, C. Michiels

*Laboratory of Biochemistry and Cellular Biology (URBC), University of Namur, 61 rue de Bruxelles, 5000 Namur, Belgium. E-mail : audrey.sermeus@fundp.ac.be*

- 37. ADJUSTING PREDICTION MODELS FOR OVARIAN TUMOR CLASSIFICATION TO NEW CLINICAL SETTINGS.**

**Ben Van Calster**<sup>1</sup> Lieven De Clercq, Caroline Van Holsbeke, Artur Czekierdowski, Stefano Guerriero, Luca Savelli, Dorella Franchi, Daniela Fischerova, Jingzhang, Elisabeth Epstein, Lil Valentin, Antonia C Testa, Sabine Van Huffel, Dirk Timmerman

Presenting author : Dept Electrical Engineering (ESAT-SCD) and Leuven's Kankerinstituut, Katholieke Universiteit Leuven, Belgium

Kasteelpark Arenberg 10, B-3001 Leuven, Belgium

Tel: 0032 16 321925 ; Mail: ben.vancalster@esat.kuleuven.be

- 38. GENE METHYLATION PROFILING FOR BREAST CANCER SUBTYPE DISCRIMINATION USING ILLUMINA'S INFINIUM TECHNOLOGY**

**Ilse Van der Auwera**<sup>1</sup>, Wayne Yu<sup>2</sup>, Ridha Limame<sup>1</sup>, Peter van Dam<sup>1</sup>, Eric Van Marck<sup>1</sup>, Peter Vermeulen<sup>1</sup>, Luc Dirix<sup>1</sup> and Steven Van Laere<sup>1</sup>

<sup>1</sup>Translational Cancer Research Group (Laboratory of Pathology, University of Antwerp/University Hospital Antwerp; Oncology Centre, General Hospital St-Augustinus, Wilrijk, Belgium)

<sup>2</sup> The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, US

- 39. DECREASED ANTI-PROLIFERATIVE ACTIVITY OF GEMCITABINE BY MYCOPLASMA INFECTION**

**Johan Vande Voorde**, Annelies Bronckaers, Sandra Liekens and Jan Balzarini

Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

**40. ROLE OF P16/INK4A AS A PROGNOSTIC FACTOR FOR RADIOTHERAPY RESPONSE IN OROPHARYNGEAL CARCINOMA.**

**E.-J. Van Limbergen, M.D.**<sup>1</sup>, E. Hauben M.D., PhD<sup>3</sup>, S. Nuyts, M.D. PhD<sup>1,2</sup>.

1 - Fellowship Research Foundation Flanders – FWO; Laboratory of Experimental Radiotherapy, Leuven Kanker Instituut, University Hospitals Leuven, Leuven, Belgium

2 - Department of Radiation Oncology, Leuven Kanker Instituut, University Hospitals Leuven, Leuven, Belgium

3 - Department of Pathology, Leuven Kanker Instituut, University Hospitals Leuven, Leuven, Belgium

**41. INFLUENCE OF LOW OXYGEN CONDITIONS ON THE RADIOSENSITISING EFFECT OF GEMCITABINE, IN P53 WILD TYPE AND P53 DEFICIENT NON-SMALL CELL LUNG CARCINOMA CELLS.**

**An Wouters**<sup>1</sup>, Bea Pauwels<sup>1</sup>, Hilde A.J. Lambrechts<sup>1</sup>, Greet G.O. Pattyn<sup>1</sup>, Paul Meijnders<sup>2</sup>, Jan B. Vermorcken<sup>1</sup>, and Filip Lardon<sup>1</sup>

1 - Dept. of Medical Oncology, Universiteit Antwerpen, Wilrijk, Belgium

2 - Dept. of Radiotherapy, University Radiotherapy Antwerp (URA), Wilrijk, Belgium

Tel: +32 3 265 25 76, Email: An.Wouters@ua.ac.be